Advancements and Considerations in the Treatment of Heart Failure

A panel of key opinion leaders in cardiology and pharmacy provides a lively discussion on currently available and emerging therapeutic approaches for the treatment of heart failure.

EP. 1: Defining Heart Failure: HFpEF and HFrEF

June 28th 2021

Ryan Jacobsen, PharmD, BCPS leads a discussion on defining heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) as well as the importance of staging and functional classification criteria.

EP. 2: Diagnosis and Treatment Approaches in Heart Failure

June 28th 2021

Alexandra Goncharenko, PharmD, BCPS, BCCP reviews factors that may influence treatment approaches for heart failure and emphasizes the importance of diagnosis to begin maximally tolerated doses of guideline-directed medical therapy.

EP. 3: Historical Treatment Options in Heart Failure

July 6th 2021

Key opinion leader in pharmacy, Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA, provides insight into the history of conventional treatment approaches in heart failure.

EP. 4: ARNIs for the Treatment of Heart Failure

July 6th 2021

A panel of experts builds a discussion on the role of angiotensin receptor-neprilysin inhibitors for the management of heart failure and highlights the importance of considering patient adherence and cost burden.

EP. 5: The Role of Ivabradine in Patients with Heart Failure

July 12th 2021

Key opinion leaders in cardiology and pharmacy consider the role of ivabradine to reduce heart rate and lower the risk of hospitalization for patients with heart failure.

EP. 6: Safety and Efficacy of SGLT2 Inhibitors in Heart Failure

July 12th 2021

Experts in cardiology and pharmacy provide an overview of the cardiac benefit of SGLT2 inhibitors by discussing their mechanism of action, safety, efficacy, and cost burden for patients with heart failure.

EP. 7: The Recent FDA Approval of Vericiguat for Heart Failure

July 19th 2021

A thought leader in the pharmacologic management of heart failure, Alexandra Goncharenko, PharmD, BCPS, BCCP, reviews the mechanism of action of vericiguat and considers its place in the treatment landscape.

EP. 8: The Goals of Guideline-Directed Medical Therapy in HF

July 19th 2021

Panelists consider the goals of guideline-directed medical therapy and reflect on how recent updates to clinical practice guidelines may impact therapeutic pathways.

EP. 9: Goals of Pharmacologic Maintenance of Heart Failure

July 26th 2021

Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA reviews the goals of pharmacologic maintenance of heart failure and comments on the importance of social determinants of health, health system efficiency, and patient education.

EP. 10: Optimizing Care for Patients With Heart Failure

July 26th 2021

Key opinion leaders in the pharmacologic management of heart failure share insights on optimizing care by using a patient-centered approach and shared decision-making.